That time frame LF gave is getting closer "A realistic timeframe for investors to look for, for the completion of a partnering deal, would be by the end of 2014." but I have a sneaky suspicion that we may hear something from Smith and Nephew soon as well, I wonder which will come first? Something else to consider is Novoskin, is that something else we could hear about soon or an update on the burns trial, I reckon we may get to hear SOMETHING before the upcoming AGM somehow?
"Calzada (CZD: $0.115) reached a major milestone this week with clearance received from the FDA to sell its first product into the US wound healing market.
That product is the NovoPore dressing that will be used in Topical Negative Pressure (TNP) dressings, a market that is work in excess of $400 million.
Calzada's product was tested against the market leading product and gold standard, Granufoam from KCI. In an 18 patient trial, it was found that Calzada's NovoPore achieved less fragmentation into the wound and was easier to remove with less bleeding. Calzada's product also has the advantage of being biodegradable, so removing all fragments is less important that with other products.
NovoPore is made from biodegradable polyurethane.
The next step in commercialising the product is to partner it with one of the existing marketers of the TNP products.
There are around five major players in this field and Calzada is in discussion with most of them according to Laurent Fossaert, CEO of Polynovo Biomaterials, a fully owned subsidiary of Calzada.
Calzada will seek to retain manufacturing control of the product, which is made at the company's facility in Melbourne.
A realistic timeframe for investors to look for, for the completion of a partnering deal, would be by the end of 2014.
Fossaert said the approval is a big tick in the box for the company, being important for getting the next products on the market using the same technology , and important also for potential partners. The approval lowers the risk of the entire technology platform, which can now be leveraged to bring other products to market believes Fossaert."
CZD Price at posting:
9.8¢ Sentiment: Buy Disclosure: Held
